Amarin Corp Plc (AMRN)

[Whalatane]

Ram. part 2 . Theres plenty of downside risk IMHO
Risk that MITIGATE fails to show any risk reduction using Vascepa to prevent , shorten , reduce effects etc of Covid .
Risk that Kaiser did not continue to dispense Vascepa to these ASCVD patients who should continue to be on Vascepa anyway .
Risk that AMRN declined to fund / provide Vascepa beyond the initial 12 mths in the trial and thus lost the opportunity for longer term CV data to support R-IT
Kiwi